

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	PharmAust Limited
<b>ABN</b>	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Robert Charles Bishop
<b>Date of last notice</b>	16 March 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	The securities are held by Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.  Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
<b>Date of change</b>	26 June 2018
<b>No. of securities held prior to change</b>	6,079,328 Ordinary Fully Paid Shares 913,222 Unlisted Options 30/09/2016 – 12c
<b>Class</b>	Ordinary Fully Paid Shares
<b>Number acquired</b>	500,000 Ordinary Fully Paid Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$20,000.00
<b>No. of securities held after change</b>	6,579,328 Ordinary Fully Paid Shares 913,222 Unlisted Options 30/09/2016 – 12c
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	<p>Milestone Shares  The milestones for the issue of Shares under Resolution 4 approved by shareholders at the General Meeting on 5 August 2013:</p> <p>Milestone 1 - One of the Pitney Products being granted investigational new drug (IND) status from the US Food and Drug Administration and Pitney receiving an IND number issued by the US Food and Drug Administration within 5 years of the date of settlement of the Pitney Transaction.</p> <p>Milestone 2 - Commencement of treatment of the first patient under a Phase II Trial with the product Albendazole within 5 years of the date of settlement of the Pitney Transaction.</p> <p>Milestone 3 - Commencement of treatment of the first patient under a Phase II Trial using the product Monepantel within 5 years of the date of settlement of the Pitney Transaction.</p>

---

+ See chapter 19 for defined terms.

For personal use only